{"id":998499,"date":"2026-08-27T08:22:03","date_gmt":"2026-08-27T12:22:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/"},"modified":"2026-08-27T08:22:03","modified_gmt":"2026-08-27T12:22:03","slug":"biomerica-announces-2-23-million-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/","title":{"rendered":"Biomerica Announces $2.23 Million Financing\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:15pt;margin-bottom:10pt\">Financing priced at $1.60 with no warrants or discount<\/li>\n<li style=\"margin-bottom:5pt\">B. Riley Principal Capital and B. Riley executives, as well as Biomerica&#8217;s CEO and all members of Biomerica\u2019s Board of Directors participated in the financing<\/li>\n<li style=\"margin-bottom:5pt\">Proceeds expected to strengthen the Company&#8217;s balance sheet and fund operations and support the Board&#8217;s ongoing evaluation of potential strategic opportunities, including partnerships and business combinations\n<\/li>\n<\/ul>\n<p>IRVINE, Calif., Aug.  27, 2026  (GLOBE NEWSWIRE) &#8212; Biomerica, Inc. (Nasdaq: BMRA) (\u201cBiomerica\u201d or the \u201cCompany\u201d), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company\u2019s common stock at a price of $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the Company.<\/p>\n<p>The financing was priced at $1.60 at the time the definitive agreements were entered into and includes no warrants or discounted securities.<\/p>\n<p>Participation in the financing included B. Riley Principal Capital , certain executives and employees of B. Riley Securities, Inc. (\u201cB. Riley\u201d), the Company&#8217;s Chief Executive Officer, and all members of the Company&#8217;s Board of Directors, reflecting meaningful alignment between outside investors and Company leadership.<\/p>\n<p>Following the closing of the financing, the Company expects to have approximately 4,588,968 shares of the Company\u2019s common stock outstanding on a pro forma basis, with the shares issued in the financing representing approximately 30.4% of pro forma shares outstanding.<\/p>\n<p>The Company intends to use the proceeds to strengthen its balance sheet and fund operations as its Board of Directors continues to evaluate a range of potential strategic opportunities intended to maximize shareholder value.<\/p>\n<p>\n        <strong>B. Riley Securities Engagement<\/strong>\n      <\/p>\n<p>Biomerica also announced that it has engaged B. Riley as its exclusive financial advisor in connection with the evaluation and potential pursuit of potential strategic opportunities.<\/p>\n<p>Under the engagement, B. Riley may assist the Company in reviewing, evaluating and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs and other strategic combinations.<\/p>\n<p>\n        <strong>About Biomerica (NASDAQ: BMRA)<\/strong>\n      <\/p>\n<p>Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital\/clinical laboratories for detection and\/or treatment of medical conditions and diseases. The Company&#8217;s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. The Company&#8217;s Board of Directors continues to evaluate potential strategic opportunities with the goal of maximizing long-term shareholder value.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>The Private Securities Litigation Reform Act of 1995 provides a \u201csafe harbor\u201d for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company&#8217;s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company&#8217;s products and tests, FDA and\/or international regulatory authorization for the Company&#8217;s products to be marketed and sold, including the inFoods IBS product, and the Company&#8217;s other current and future products, the possible expansion into other markets, uniqueness of the Company&#8217;s products, accuracy of the Company&#8217;s tests and products, future use of the Company&#8217;s products by physicians to treat their patients, potential revenues from the sale of current or future products, reimbursement and coverage decisions by Centers for Medicare &amp; Medicaid Services, Medicare Administrative Contractors coverage, and private insurers, the acceptance of the Company&#8217;s research at medical conferences, the clinical significance of the Company&#8217;s real-world and clinical trial data, and the Company&#8217;s evaluation and pursuit of strategic opportunities, including potential acquisitions, mergers, joint ventures, partnerships, spin-offs and other strategic combinations. Such forward-looking information is based upon the current beliefs and expectations of management and involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company&#8217;s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company&#8217;s products; availability of the Company&#8217;s test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import\/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; regulatory compliance and oversight; the Company&#8217;s ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies; fluctuations in the Company&#8217;s operating results due to its business model and expansion plans; downturns in international and\/or national economies; the Company&#8217;s ability to raise additional capital; the competitive environment in which the Company will be competing; the Company&#8217;s dependence on strategic relationships; and the Company&#8217;s ability to identify, negotiate and complete any strategic transaction on favorable terms, or at all. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additional factors that could cause actual results to differ from those expressed in the forward-looking statements are discussed in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC, and available on the SEC\u2019s website (www.sec.gov). The Company is under no obligation to update any forward-looking statements after the date of this release.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong>\n      <\/p>\n<p>Zack Irani<br \/>949-645-2111<br \/>investors@biomerica.com<\/p>\n<p>Source: Biomerica, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjhiM2ViZWUtZjBkNS00MDM0LTlmNzMtYTRhNTYwOGVhYWVjLTExMDI0MzgtMjAyNi0wOC0yNy1lbg==\/tiny\/Biomerica-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Financing priced at $1.60 with no warrants or discount B. Riley Principal Capital and B. Riley executives, as well as Biomerica&#8217;s CEO and all members of Biomerica\u2019s Board of Directors participated in the financing Proceeds expected to strengthen the Company&#8217;s balance sheet and fund operations and support the Board&#8217;s ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) &#8212; Biomerica, Inc. (Nasdaq: BMRA) (\u201cBiomerica\u201d or the \u201cCompany\u201d), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company\u2019s common stock at a price of $1.60 per share, expected to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biomerica Announces $2.23 Million Financing\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-998499","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Financing priced at $1.60 with no warrants or discount B. Riley Principal Capital and B. Riley executives, as well as Biomerica&#8217;s CEO and all members of Biomerica\u2019s Board of Directors participated in the financing Proceeds expected to strengthen the Company&#8217;s balance sheet and fund operations and support the Board&#8217;s ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) &#8212; Biomerica, Inc. (Nasdaq: BMRA) (\u201cBiomerica\u201d or the \u201cCompany\u201d), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company\u2019s common stock at a price of $1.60 per share, expected to &hellip; Continue reading &quot;Biomerica Announces $2.23 Million Financing\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T12:22:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biomerica Announces $2.23 Million Financing\u00a0\",\"datePublished\":\"2026-08-27T12:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/\"},\"wordCount\":911,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/\",\"name\":\"Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\",\"datePublished\":\"2026-08-27T12:22:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomerica-announces-2-23-million-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomerica Announces $2.23 Million Financing\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/","og_locale":"en_US","og_type":"article","og_title":"Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk","og_description":"Financing priced at $1.60 with no warrants or discount B. Riley Principal Capital and B. Riley executives, as well as Biomerica&#8217;s CEO and all members of Biomerica\u2019s Board of Directors participated in the financing Proceeds expected to strengthen the Company&#8217;s balance sheet and fund operations and support the Board&#8217;s ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) &#8212; Biomerica, Inc. (Nasdaq: BMRA) (\u201cBiomerica\u201d or the \u201cCompany\u201d), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company\u2019s common stock at a price of $1.60 per share, expected to &hellip; Continue reading \"Biomerica Announces $2.23 Million Financing\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-27T12:22:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biomerica Announces $2.23 Million Financing\u00a0","datePublished":"2026-08-27T12:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/"},"wordCount":911,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/","name":"Biomerica Announces $2.23 Million Financing\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=","datePublished":"2026-08-27T12:22:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjkyMyM3ODA1NDU2IzIwOTA4Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomerica-announces-2-23-million-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biomerica Announces $2.23 Million Financing\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=998499"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=998499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=998499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=998499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}